12/11
05:34 pm
autl
T-cell Malignancies Market Dynamics: Key Insights on Acute Lymphocytic Leukemia, Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Adult T-cell Leukemia/Lymphoma | DelveInsight [Yahoo! Finance]
Medium
Report
T-cell Malignancies Market Dynamics: Key Insights on Acute Lymphocytic Leukemia, Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Adult T-cell Leukemia/Lymphoma | DelveInsight [Yahoo! Finance]
12/11
05:31 pm
autl
T-cell Malignancies Market Dynamics: Key Insights on Acute Lymphocytic Leukemia, Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Adult T-cell Leukemia/Lymphoma | DelveInsight
Medium
Report
T-cell Malignancies Market Dynamics: Key Insights on Acute Lymphocytic Leukemia, Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Adult T-cell Leukemia/Lymphoma | DelveInsight
12/11
05:31 pm
autl
T-cell Malignancies Market Dynamics: Key Insights on Acute Lymphocytic Leukemia, Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Adult T-cell Leukemia/Lymphoma | DelveInsight
Medium
Report
T-cell Malignancies Market Dynamics: Key Insights on Acute Lymphocytic Leukemia, Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Adult T-cell Leukemia/Lymphoma | DelveInsight
12/9
07:45 pm
autl
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 [Yahoo! Finance]
Medium
Report
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 [Yahoo! Finance]
12/9
07:30 pm
autl
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Medium
Report
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
12/5
07:27 pm
autl
Autolus Therapeutics plc (AUTL): A Bull Case Theory [Yahoo! Finance]
Low
Report
Autolus Therapeutics plc (AUTL): A Bull Case Theory [Yahoo! Finance]
12/5
08:01 am
autl
Autolus Therapeutics plc (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
Medium
Report
Autolus Therapeutics plc (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
12/4
05:31 pm
autl
Stay Ahead in Hematology: Strategic Competitive Intelligence for Informed Decision-Making | DelveInsight
Medium
Report
Stay Ahead in Hematology: Strategic Competitive Intelligence for Informed Decision-Making | DelveInsight
12/4
05:31 pm
autl
Stay Ahead in Hematology: Strategic Competitive Intelligence for Informed Decision-Making | DelveInsight
Medium
Report
Stay Ahead in Hematology: Strategic Competitive Intelligence for Informed Decision-Making | DelveInsight
12/2
07:10 am
autl
Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine [Yahoo! Finance]
Low
Report
Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine [Yahoo! Finance]
12/2
07:00 am
autl
Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
Low
Report
Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
11/19
05:31 pm
autl
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
Medium
Report
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
11/19
05:31 pm
autl
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
Medium
Report
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
11/18
08:06 am
autl
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $7.60 price target on the stock, up previously from $7.00.
Medium
Report
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $7.60 price target on the stock, up previously from $7.00.
11/15
08:27 am
autl
Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023) [Yahoo! Finance]
Medium
Report
Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023) [Yahoo! Finance]
11/15
08:04 am
autl
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at Redburn Atlantic from a "neutral" rating to a "buy" rating. They now have a $13.00 price target on the stock.
Medium
Report
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at Redburn Atlantic from a "neutral" rating to a "buy" rating. They now have a $13.00 price target on the stock.
11/14
05:02 am
autl
BioNTech signs agreement to acquire Biotheus [Yahoo! Finance]
Medium
Report
BioNTech signs agreement to acquire Biotheus [Yahoo! Finance]
11/13
02:26 am
autl
Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Low
Report
Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
11/12
07:00 am
autl
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Medium
Report
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
11/11
01:07 pm
autl
Autolus secures FDA approval for CAR-T cell therapy use in ALL [Yahoo! Finance]
Low
Report
Autolus secures FDA approval for CAR-T cell therapy use in ALL [Yahoo! Finance]
11/11
08:10 am
autl
Autolus Therapeutics plc (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
High
Report
Autolus Therapeutics plc (NASDAQ: AUTL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
11/11
07:33 am
autl
What To Expect From Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings [Yahoo! Finance]
High
Report
What To Expect From Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings [Yahoo! Finance]
11/8
04:30 pm
autl
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) [Yahoo! Finance]
Medium
Report
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) [Yahoo! Finance]
11/8
04:23 pm
autl
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
Medium
Report
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
11/5
09:00 am
autl
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
Low
Report
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations